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Measurement of Interleukin-33 (IL-33) and IL-33 Receptors  
(sST2 and ST2L) in Patients with Rheumatoid Arthritis
The interleukin-33 (IL-33)/ST2 pathway has emerged as an intercellular signaling system 
that participates in antigen–allergen response, autoimmunity and fibrosis. It has been 
suggested that IL-33/ST2 signaling has been involved in the pathogenesis of rheumatoid 
arthritis (RA), because IL-33 and its receptor have been specifically mapped to RA 
synovium. The aim of this study was to determine the levels of IL-33 and sST2 in sera and 
synovial fluids in patients with RA. The serum level of IL-33 was significantly higher in 
patients with RA (294.9 ± 464.0 pg/mL) than in healthy controls (96.0 ± 236.9 pg/mL, 
P = 0.002). The synovial fluid level of IL-33 was significantly higher in RA patients than in 
osteoarthritis patients. The level of serum sST2 was higher in RA patients than in healthy 
controls (P = 0.042). A significant relationship was found between the levels of IL-33 and 
IL-1β (r = 0.311, P = 0.005), and IL-33 and IL-6 (r = 0.264, P = 0.017) in 81 RA patients. 
The levels of IL-33, sST2 and C-reactive protein decreased after conventional disease-
modifying antirheumatic drugs treatment in 10 patients with treatment-naïve RA. 
Conclusively, IL-33 is involved in the pathogenesis of RA and may reflect the degree of 
inflammation in patients with RA.
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INTRODUCTION
Interleukin-33 (IL-33) is a member of the IL-1 family, which in-
cludes IL-1α, IL-1β, IL-1 receptor antagonist, and IL-18. In hu-
mans, IL-33 is found predominantly in the skin, lung, adipocytes, 
and synovial fibroblasts (1, 2). Similar to IL-1β and IL-18, IL-33 
is considered to be produced intracellularly as pro-IL-33, which 
does not contain a signal peptide sequence for secretion, and 
then released extracellularly as mature IL-33 after cleavage. Ma-
ture IL-33 has been reported to mediate its biologic effects via 
T1/ST2 binding by activating NF-κB and MAP kinase (3).
  IL-33 binds to its receptor complex, which comprises ST2L 
and IL-1 receptor accessory protein on eosinophils, basophils, 
mast cells, natural killer (NK) cells, Th2 lymphocytes, and invari-
ant natural killer T (iNKT) cells (4). IL-33 enhances adhesion and 
CD11b expression in human eosinophils and basophils (5). IL-
33 induces the production of IL-6, IL-1β, tumor necrosis factor-α 
(TNF-α), monocyte chemotactic protein-1, and prostaglandin 
D2 production in bone marrow-derived mast cells (6). It also in-
creases the production of IL-5 and IL-13 by polarized Th2 cells 
(3) and interferon-γ (IFN-γ) production by both iNKT and NK 
cells (7).
  ST2 is a member of the IL1R/TLR superfamily. There are three 
isoforms of ST2 in humans, which are produced by differential 
splicing of a single transcript: sST2, ST2L, and ST2V. soluble(s)
ST2, the secreted soluble form, is expressed in embryonic tis-
sues, mammary tumors, and fibroblasts (8). The expression of 
ST2L, a membrane-anchored long form, is restricted to the sur-
face of Th2 cells and mast cells (3). ST2V is expressed mainly in 
gastrointestinal organs such as the stomach, large and small in-
testine, and spleen (9). Whereas ST2L mediates the effect of IL-
33 on Th2-dependent inflammatory processes, sST2 acts as a 
decoy receptor that prevents the interaction of ST2L with IL-33. 
sST2 has been implicated in the attenuation of the Th2-induced 
inflammatory response.
  Rheumatoid arthritis (RA) is a chronic inflammatory autoim-
mune disease characterized by synovitis, bone destruction with 
pannus formation, and degradation of articular cartilage. It has 
been suggested that IL-33/ST2 signaling is involved in the patho-
genesis of a wide array of diseases including asthma, fibropro-Hong Y-S, et al.  •  IL-33 and IL-33 Receptor in RA
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liferative disease, and autoimmune diseases such as systemic 
lupus erythematosus (SLE), progressive systemic sclerosis, We-
gener’s granulomatosis, and Behçet’s disease. Recent studies 
have suggested that IL-33/ST2 is involved in the pathogenesis 
of RA. IL-33 mRNA is expressed in the RA synovial membrane, 
predominantly in fibroblast-like synoviocytes. IL-33 administra-
tion exacerbates collagen-induced arthritis (CIA) in mice, and 
disease severity is reduced in mice administered with sST2-Fc 
fusion protein or anti-IL-33 monoclonal antibody (10). Injection 
of IL-33 into a joint induces localized mechanical damage or ar-
ticular hypernociception, which can be inhibited by sST2 treat-
ment in mice (11).
  In patients with RA, the level of sST2 is elevated in the serum 
(12). However, little is known about the levels of IL-33 in RA pa-
tients. In this study, we measured the levels of IL-33 and sST2 in 
sera and synovial fluids of RA patients and examined whether the 
levels of IL-33 or sST2 could reflect the degree of inflammation. 
 
MATERIALS AND METHODS
Patients
This was a multicenter study conducted by Catholic University 
and Soonchunhyang University in Korea from May 2008 to Jan-
uary 2009. Blood samples were drawn from 81 patients with RA, 
18 patients with osteoarthritis (OA), and 50 healthy subjects. Sy-
novial fluids were obtained from 16 RA patients and 10 OA pa-
tients, and IL-33 and sST2 levels were measured. RA was diag-
nosed based on the American College of Rheumatology 1987 
criteria (13). When the patients had never been received any 
kind of disease-modifying antirheumatic drugs (DMARDs), it 
was defined as “treatment-naïve”. On the other hand, treated RA 
was defined when the patients had been administered any kind 
of DMARDs. None of all the patients that were enrolled in this 
study had ever received the biological agents for the treatment of 
RA. The serum levels of IL-33, sST2, and C-reactive protein (CRP) 
were measured before and after treatment with DMARDs in 10 
treatment-naïve RA patients. 
Enzyme-linked Immunosorbent assay (ELISA) for IL-33, 
IL-1, IL-6, and ST2/IL-1 R4
The IL-33, IL-1β, and IL-6 concentrations in diluted serum and 
synovial fluid were measured by sandwich ELISA. Briefly, 4 μg/
mL of monoclonal capture antibody (R&D Systems, Minneapo-
lis, MN, USA) was added to a 96-well plate (Nunc, Rochester, NY, 
USA) and the plate was incubated for 2 hr at room temperature. 
The plate was then incubated in blocking solution comprising 
phosphate-buffered saline (PBS) containing 1% bovine serum 
albumin and 0.05% Tween 20 for 2 hr at room temperature. All 
sera and synovial fluid samples were diluted 1:2 by using PBS 
containing 1% bovine serum albumin and 0.05% Tween 20. And 
standard curves were also diluted with PBS containing 1% bovine 
serum albumin and 0.05% Tween 20.
  The test samples and standard recombinant IL-33, IL-1β, and 
IL-6 (R&D Systems) were added to the plates, and the plate was 
incubated for 2 hr at room temperature. The plate was washed 
four times with PBS containing Tween 20, 200 ng/mL of bioti-
nylated detection monoclonal antibodies (R&D Systems) was 
added, and the plate was incubated for 2 hr at room tempera-
ture. The plate was washed, streptavidin–alkaline-phosphatase 
(Sigma-Aldrich, St Louis, MO, USA; diluted 1:2,000) was added, 
and the reaction was allowed to proceed for 2 hr at room tem-
perature. The plate was washed four times, and 1 mg/mL of p-
nitrophenyl phosphate dissolved in diethanolamine (both from 
Sigma-Aldrich) was added to induce the color reaction, which 
was stopped by adding 50 μL of 1 N NaOH. The optical density 
at 405 nm was measured on an automated microplate reader 
(VERSAmax, Molecular Devices, Palo Alto, CA, USA). A standard 
curve was drawn by plotting optical density versus the log of the 
concentrations of IL-33, IL-1β, and IL-6. The ST2/IL-1R4 level was 
measured using the DuoSet ELISA kit (R&D Systems) following 
the manufacturer’s protocol.
Immunohistochemical staining for IL-33 and ST2/IL-1 R4
Biopsy specimens from the synovium of patients with RA and 
OA were surgically removed and placed in 4% paraformalde-
hyde solution overnight at 4°C. The fixed tissues were embed-
ded in paraffin and sectioned at 7-μm thickness. Paraffin-em-
bedded slides were deparaffinized by immersion in xylene and 
then dehydrated in ethanol. Sections were depleted of endoge-
nous peroxidase activity by adding methanolic H2O2. Immuno-
histochemical staining was performed using a Vectastain ABC 
kit (Vector, Peterborough, UK). After overnight incubation at 4°C 
with anti-IL-33 and anti-ST2/IL-1 (R&D Systems), samples were 
incubated for 20 min with the secondary antibodies, biotinylat-
ed anti-goat IgG and then incubated with streptavidin–peroxi-
dase complex for 1 hr followed by incubation with 3,3´-diami-
nobenzidine (Dako, Glostrup, Denmark) for 5 min. The sections 
were counterstained with Mayer’s hematoxylin, and the sam-
ples were photographed with an Olympus (Tokyo, Japan) pho-
tomicroscope.
Statistical analysis
All data are expressed as the mean ± standard deviation (SD). Con-
tinuous variables from the study were analyzed by the ANOVA 
and/or the Student’s t test with a parametric distribution or the 
Mann-Whitney U test with a nonparametric distribution. Cate-
gorical data were compared using the chi-square test. Correla-
tions between each variable were evaluated using the Spearman 
rank-order correlation test. All statistical analyses were performed 
using SPSS software (Chicago, IL, USA). Differences of P < 0.05 
were considered significant.Hong Y-S, et al.  •  IL-33 and IL-33 Receptor in RA
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Ethic statement
The study protocol was approved by the institutional review 
board of The Catholic University of Korea (HCMC08OT006) and 
Soonchunhyang University, and signed informed consent was 
obtained from each patient.
RESULTS
Baseline demographic and clinical characteristics
The clinical and serological characteristics of the patients are 
described in Table 1. None of the patients with RA had admin-
istered any kind of anti-TNF therapy. Other medications in Table 
1 include sulfasalazine, leflunomide and cyclosporine. In the 
patients with OA, 7 out of 18 were taken NSAIDs only and the 
rest were not administered any kind of medications. 
IL-33 and sST2 levels in sera and synovial fluids
As shown in Fig. 1A, the mean value of IL-33 was significantly 
higher in sera of RA patients than those of healthy controls (294.9 
± 464.0 and 95.9 ± 236.9 pg/mL, respectively, P = 0.002). The se-
rum levels of IL-33 were significantly higher in patients with OA 
(310.3 ± 462.6 pg/mL) than controls (P = 0.015). The sST2 serum 
concentration was significantly higher in patients with RA (767.1 
± 1,059.5 pg/mL) than in healthy controls (455.4 ± 621.1 pg/mL, 
P = 0.042). In contrast to IL-33, the serum levels of sST2 did not 
differ between the patients with OA (330.4 ± 244.3 pg/mL) and 
Table 1. Clinical and serological characteristics of patients
Parameters RA  OA  HC
Age (yr)   52.1 ± 13.3
†,‡   61.6 ± 7.7
‡  39.8 ± 10.1
No. (female/male)  81 (62/19)* 18 (18/0) 50 (40/10)
No. (treatment-naïve RA) 10
Medication
   MTX
   Steroid
   HCQ
   NSAID
   Others
 
51/81
50/81
21/81
41/81
16/81
 
CRP (mg/L) 19.1 ± 23.6
†    1.1 ± 0.9
C-ESR (mm/hr) 32.6 ± 25.7
† 16.6 ± 8.6
Values are expressed as mean ± SD. *P < 0.05 vs OA; 
†P < 0.01 vs OA; 
‡P < 0.01 vs 
control. RA, rheumatoid arthritis; OA, osteoarthritis; HC, healthy control; MTX, metho-
trexate; HCQ, hydrochloroquine; NSAID, nonsteroidal anti-inflammatory drug.
Fig. 1. Interleukin 33 (IL-33) levels in sera (A) or synovial fluids (B) from the patients with OA and RA comparing to HC. HC, healthy controls; OA, osteoarthritis; RA, rheumatoid 
arthritis. Symbols represent individual samples. 
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healthy controls but that were significantly lower in patients with 
OA than RA. 
  The synovial fluid levels of IL-33 and sST2 were also measured 
in 16 samples of RA and 10 samples of OA. The mean level of IL-
33 was 2,235.8 ± 5,035.4 pg/mL in the synovial fluids of RA, which 
was significantly higher than those of OA (424.8 ± 40.5 pg/mL, P = 
0.015). However, the mean sST2 concentration of synovial fluid 
did not differ between the RA (2,508.3 ± 5,496.6 pg/mL) and OA 
(1,363.1 ± 2,156.7 pg/mL). These values are shown in Fig. 1B.
  Similar to the synovial fluid levels of IL-33, the expressions of 
IL-33 and ST2L in RA synovium were greater than OA synovium 
(Fig. 2). 
IL-33 and sST2 concentration in association with inflam-
matory markers 
IL-6, IL-1β, and CRP levels were also measured in sera of patients 
with RA to confirm whether IL-33 is involved in the pathogene-
sis of RA and therefore reflects inflammatory status of the dis-
ease. Significant positive relationships were found between IL-
33 and IL-1β levels (r = 0.311, P = 0.005) and IL-33 and IL-6 levels 
(r = 0.264, P = 0.017) in the 81 RA patients. The serum levels of 
sST2 also correlated significantly with both IL-6 and IL-1β levels 
in RA patients (Table 2). However, in the patients with OA, no 
significant correlation was observed between IL-33 and IL-1β 
or IL-6 levels, or between sST2 and IL-1β or IL-6 levels.
Decreased serum concentration of IL-33 and sST2 with 
DMARDs therapy 
In 10 patients with treatment-naïve RA, the levels of IL-33, sST2, 
and CRP were compared before and after DMARDs therapy. The 
9 patients out of them were administered more than 1 kind of 
DMARDs including methotrexate (MTX). MTX, hydroxychloro-
quine and sulfasalazine were administered to these patients. 
The remaining one patient received hydroxychloroquine and 
low dose steroid only because of the patient’s refusal and low 
disease activity. Low dose glucocorticoids were administered to 
all of the patients. Fig. 3 shows the individual values of IL-33 and 
sST2 before and after treatment with DMARDs. The serum levels 
of both IL-33 and sST2 decreased after DMARDs therapy in the 
patients with RA (P = 0.034 and 0.012, respectively). As CRP is 
Table 2. Correlations between laboratory data and serum IL-33 or sST2 level
RA OA
IL-33 sST2 IL-33 sST2
r P value r P value r P value r P value
IL-6 0.264 0.017 0.339 0.003 0.069 0.785 0.071 0.779
IL-1β 0.311 0.005 0.265 0.022 0.230 0.358 0.133 0.598
CRP -0.078 0.488 -0.054 0.649 -0.015 0.951 -0.006 0.981
r, Spearman’s rank correlation coefficient. RA, rheumatoid arthritis; OA, osteoarthritis; CRP, C-reactive protein.
Fig. 2. The expression of IL-33 and ST2 in the synovium of RA and OA. Immunohistochemical staining of RA synovium and OA synovium. RA, rheumatoid arthritis; OA, osteoar-
thritis. Data are representative of 5 RA and 2 OA independent samples that yielded similar results.
RA1 RA2
OA1 OA2
Anti-IL-33 Anti-IL-33
× 200 × 200
× 400 × 400
× 400 × 400
× 200 × 200
× 400 × 400
× 400 × 400
Anti-ST2 Anti-ST2Hong Y-S, et al.  •  IL-33 and IL-33 Receptor in RA
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widely used to ascertain the degree of inflammatory response, 
we also measured the serum level of CRP. Along with IL-33 and 
sST2, CRP levels also decreased significantly after treatment with 
DMARDs in the patients with treatment-naïve RA. In addition, 
significant positive relationship (r = 0.827, P < 0.01) was found 
between the degree of IL-33 concentration decrease and that of 
CRP after treatment. In case of sST2, there was no relationship 
with the changes of CRP concentration (r = 0.547, P = 0.203).
 
DISCUSSION
In our study, the serum level of IL-33 was higher in the patients 
with RA as well as OA than healthy controls. And the IL-33 con-
centration was higher in RA synovial fluids than those of OA.
  Palmer et al. (14) reported IL-33 staining in endothelial cells 
in both inflamed RA synovium and normal synovial tissue. While 
the resting synovial fibroblasts express little or no IL-33, its ex-
pression is markedly increased by TNF-α and IL-1β (15). Schmitz 
et al. (3) demonstrated that activated dendritic cells (DCs) and 
macrophages express low quantities of human IL-33 mRNA. 
The synovial fluids of RA patients and perivascular regions of 
RA synovium exhibit increased numbers of myeloid and plas-
macytoid DCs (16). Macrophages are abundant in the inflamed 
synovial membrane and activation of macrophages in the in-
flamed synovial membrane correlates with the severity of rheu-
matoid arthritis (17). Therefore, synovial fibroblasts, endothelial 
cells, activated DCs, and macrophages may be the main source 
of IL-33 in synovial fluid from RA patients (3, 15).  
  Within our knowledge, there is only one study showing serum 
level of IL-33 in OA patients. In that report (18), serum level of IL-
33 in OA patients is significantly lower than that of RA. Although 
OA is still generally considered a degenerative disorder, the de-
velopment and progression of OA are now believed to involve 
inflammation even in the early stages of the disease. Secreted in-
flammatory factors such as proinflammatory cytokines are crit-
ical mediators of the disturbed metabolism and enhanced ca-
tabolism of joint tissue involved in OA. IL-1β, TNF and IL-6 seem 
to be the main proinflammatory cytokines involved in the patho-
physiology of OA (19). 
  Fig. 1A showed elevated level of IL-33 in sera of both RA and 
OA patients comparing to those of healthy controls. It seems 
odds that serum level of IL-33 does not differ between the pa-
tients with RA and OA. Since the OA patients were older than 
RA in our study (61.6 ± 7.7 and 52.1 ± 13.3 yr, respectively), it is 
conceivable that serum level of IL-33 is affected by aging. So, we 
determined to compare the serum levels of IL-33 in younger OA 
patients (≤ 65 yr) with older (> 65 yr) to ascertain the impact of 
age on IL-33 level. The mean value of serum IL-33 was not dif-
ferent between the two groups (P = 0.167). And also, there was 
no difference in IL-33 concentration between OA patients and 
age, sex-matched RA patients (P = 0.313). Conclusively, the age 
factor did not seem to influence the level of circulating IL-33 in 
OA patients in this study. We think that these results could sup-
port the above belief in OA as an inflammatory disease. 
  Considering from another aspect, administration of glucocor-
ticoids could reduce the serum level of IL-33 in the patients with 
RA. As showed in Table 1, over half of the RA patients were taken 
low dose of oral glucocorticoids. On the contrary, none of the 
OA patients was taken steroids. It is well known that glucocorti-
coids suppress many function in activated monocyte/macro-
phages, including the release of TNF-α. The use of oral glucocor-
ticoids in RA patients might affect the serum concentration of 
TNF-α and consequently reduce the IL-33. This presumption 
could be supported by the recently published data that serum 
concentrations of IL-33 were reduced after anti-TNF therapy (18). 
  Although the mean concentration of serum IL-33 is not differ-
ent to our surprise, the level of IL-33 in OA synovial fluids is sig-
nificantly lower than that of RA. We assume that this discordant 
finding between the serum and synovial fluid might imply the 
different milieu between RA and OA joints. 
  One of our study limitations is lack of disease activity, such as 
Disease Activity Score 28 (DAS28) for RA and Western Ontario 
Fig. 3. The serum concentration of IL-33, sST2 and CRP before and after DMARDs therapy in patients with treatment-naïve RA. RA, rheumatoid arthritis; CRP, C-reactive pro-
tein; DMARDs, disease-modifying antirheumatic drugs.
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and McMaster Universities (WOMAC) for OA. Although we did 
not estimate the disease activity, Matsuyama et al. (20) reported 
that DAS-28 based on C-reactive protein levels (DAS28-CRP) 
were significantly higher in patients with detectable levels of IL-
33 in sera than in those with undetectable levels. Despite this 
limitation, our study showed the similar trend of IL-33, sST2 and 
CRP changes after treatment. That could suggest the usefulness 
of IL-33 as one of the inflammatory markers such as CRP in RA. 
On the contrary, Mu et al. presented that the level of serum IL-33 
was correlated only with the production of IgM and anti-citrul-
linated peptide antibody but not correlated with the score of the 
disease activity index (18).
  It is well known that IL-6 and IL-1β are inflammatory cyto-
kines. We discovered significant positive relationships between 
IL-33 and IL-1β levels, and IL-33 and IL-6 levels in the RA sera. 
Actually, Xu et al. (15) showed that IL-33 increases the levels of 
IL-1β, IL-6, IL-13, and chemokines produced in vitro by bone 
marrow-derived mast cells from wild-type but not from ST2
–/– 
DBA/1 mice. Palmer et al. (14) reported that an anti-ST2 block-
ing antibody inhibited IL-33-induced IL-6 secretion. These results 
suggest that increased IL-33 leads to upregulation of inflamma-
tory cytokines such as IL-1β and IL-6 in patients with RA. There-
fore, we think that serum level of IL-33 could partially reflect the 
RA disease activity more than CRP alone does. Certainly, further 
research should be performed to ascertain the utility of IL-33 as 
biomarker for assessing disease activity in patient with RA. 
  In contrast to RA, we failed to find any significant correlation 
between IL-33 and IL-6 or IL-1β in sera of OA. As showed in Fig. 
1A, sera of the OA showed elevated level of IL-33 comparable to 
that of RA. So, it is plausible that the levels of other cytokines that 
increase IL-33 production, which we did not measure, might be 
increased in the patients with OA. 
  In our study, the serum level of sST2 was higher in patients 
with RA than OA, but the concentration of sST2 in synovial fluid 
did not differ significantly. The comparable concentration of 
sST2 in OA synovial fluid to that of RA suggested the possibility 
of relatively higher inflammatory milieu in RA synovium, judg-
ing on the fact that sST2 acts as a decoy receptor that prevent the 
interaction of ST2L with IL-33. To our knowledge, this is the first 
report to examine sST2 levels in sera and synovial fluids from RA 
patients and to compare these values with those in OA patients 
and healthy controls. Kuroiwa et al. measured serum sST2 levels 
in patients with autoimmune diseases including SLE, RA, sys-
temic sclerosis, Wegener’s granulomatosis, and Behcet’s disease 
(12). However, they did not compare the sST2 levels of serums 
nor that of synovial fluids from patients with these different au-
toimmune rheumatic diseases and healthy controls.
  sST2 is secreted by mouse fibroblasts or macrophages or by 
human monocytes stimulated with proinflammatory cytokines 
and anti-CD3-activated Th2 clones (8). Therefore, it is possible 
that the inflammatory milieu is responsible for the increased lev-
el of sST2 in synovial fluid. Our present data also showed that 
serum sST2 level as well as IL-33 decreased following DMARDs 
therapy in treatment-naïve RA patients. This observation sug-
gests that the inflammatory state is involved in the production 
of sST2 in patients with RA. 
  We found that ST2L was expressed in the RA synovium but 
we detected no ST2L expression in the OA synovium. The expres-
sion of ST2L is restricted to the surface of Th2 cell and mast cells 
(3), and is implicated in regulating Th2-associated immune re-
sponses, although ST2L can also promote Th1-type responses 
under certain conditions (21). The regulation of ST2L expression 
can be influenced by surrounding mediators. For example, IL-4 
enhances and IFN-γ suppresses ST2L expression on Th2 cells 
(22). Although RA is considered to be mediated by Th1/Th17 
cells, the expression of IL-4 is significantly elevated early in RA 
(23). Liew et al. (24) suggested that in early RA, IL-33 produced 
by synovial fibroblasts and synovial endothelial cells induces a 
Th2-type response. 
  The infiltration and activation of mast cells in the synovium 
are involved in the pathogenesis of RA (15). Liew et al. (24) also 
proposed that in established RA, IL-33 causes mast cell-medi-
ated inflammation, which amplifies the Th17 cell response. In 
addition to mast cell, recent report (25) elucidated that IL-33 re-
ceptor was also expressed in synovial tissue, macrophage and 
activated neutrophil and IL-33 induced neutrophil migration by 
activating synoviocytes and macrophage in animal model. In 
that study, it was also showed that anti-TNF alpha therapy pre-
vented IL-33-induced neutrophil migration in patients with RA. 
The RA patients included in our study had established RA, and 
we hypothesized that the increased expression of ST2L in the 
RA synovium would be caused by increased infiltration of mast 
cells or neutrophils. However, in this study we did not confirm 
the phenotype of cells expressing ST2L.
  Whereas ST2L mediates the inflammatory effect of IL-33, sST2 
has immunosuppressive activity by acting as a decoy receptor 
for IL-33 or has a direct anti-inflammatory action (8). Therefore, 
increased expression of sST2 could be a physiological mecha-
nism to suppress the damaging inflammatory responses induced 
by IL-33. An anti-inflammatory action of the membrane-bound 
ST2 has been also suggested (26). 
  Although recombinant pro-IL-33 is cleaved by recombinant 
caspase-1 in vitro (3), the in vivo role of caspase-1 in the cleav-
age of pro-IL-33 remains controversial (27). There are many con-
troversial results about IL-33 production from various kinds of 
cells. Actually, caspase-1-, and caspase-8-independent IL-33 
production by macrophage and mast cells was also showed in 
recent report (28). And although pro-IL-33 was demonstrated 
to show biologic activity in inducing mast cell activation, cleav-
age of pro-IL-33 by caspase-1 in vitro resulted in loss of that bio-
logic activity in a few reports (29). Concerning about the conver-
sion of IL-33, it is awkward to conclude circulating IL-33 itself is Hong Y-S, et al.  •  IL-33 and IL-33 Receptor in RA
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biologically active.
  To define the role of the IL-33/ST2 system in the pathogene-
sis of a disease, it is necessary to examine the expression of IL-
33, sST2, and ST2L simultaneously. To our knowledge, our study 
is the first to measure serum IL-33 and sST2 levels simultane-
ously in patients with RA and OA.
  In conclusion, this study demonstrated that IL-33 was signifi-
cantly elevated in the sera and synovial fluids of RA and that se-
rum level of IL-33 correlated with that of IL-1β and IL-6. The se-
rum concentration of sST2 was also higher in RA than in healthy 
controls. Serum IL-33 and sST2 levels decreased together with 
CRP, after DMARDs therapy in patients with treatment-naïve 
RA. Our results suggest that IL-33 is involved in the pathogene-
sis of RA and may reflect the degree of inflammation in patients 
with RA. Further studies are needed to define the role of elevat-
ed sST2 level in patients with RA.
 
REFERENCES
1. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 
gene family member, is expressed in human adipocytes. Biochem Biophys 
Res Commun 2009; 384: 105-9.
2. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, Mu 
R, Tay HK, McKenzie AN, McInnes IB, Melendez AJ, Liew FY. IL-33 ex-
acerbates autoantibody-induced arthritis. J Immunol 2010; 184: 2620-6.
3. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, 
Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein 
RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 recep-
tor-related protein ST2 and induces T helper type 2-associated cytokines. 
Immunity 2005; 23: 479-90.
4. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Küchler AM. Interleu-
kin-33-cytokine of dual function or novel alarmin? Trends Immunol 
2009; 30: 227-33.
5. Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, 
Saito H, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M. Interleu-
kin-33 enhances adhesion, CD11b expression and survival in human eo-
sinophils. Lab Invest 2008; 88: 1245-53.
6. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Inter-
leukin (IL)-33 induces the release of pro-inflammatory mediators by mast 
cells. Cytokine 2007; 40: 216-25.
7. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, Gombert JM, 
Schneider E, Dy M, Gourdy P, Girard JP, Herbelin A. The pro-Th2 cyto-
kine IL-33 directly interacts with invariant NKT and NK cells to induce 
IFN-gamma production. Eur J Immunol 2009; 39: 1046-55.
8. Trajkovic V, Sweet MJ, Xu D. T1/ST2: an IL-1 receptor-like modulator of 
immune responses. Cytokine Growth Factor Rev 2004; 15: 87-95.
9. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, Tom-
inaga S. Tissue distribution and subcellular localization of a variant form 
of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 
2001; 285: 1377-83.
10. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of mu-
rine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004; 173: 
145-50.
11. Verri WA Jr, Guerrero AT, Fukada SY, Valerio DA, Cunha TM, Xu D, Fer-
reira SH, Liew FY, Cunha FQ. IL-33 mediates antigen-induced cutaneous 
and articular hypernociception in mice. Proc Natl Acad Sci U S A 2008; 
105: 2723-8.
12. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of 
human ST2 protein in the sera of patients with autoimmune diseases. 
Biochem Biophys Res Commun 2001; 284: 1104-8.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, 
Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell 
DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Gunder 
GG. The American Rheumatism Association 1987 revised criteria for the 
classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
14. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, 
Finckh A, Smith DE, Gabay C. Inhibition of interleukin-33 signaling at-
tenuates the severity of experimental arthritis. Arthritis Rheum 2009; 60: 
738-49.
15. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-
Stolarska M, McKenzie AN, McInnes IB, Liew FY. IL-33 exacerbates an-
tigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 
2008; 105: 10913-8.
16. Cavanagh LL, Boyce A, Smith L, Padmanabha J, Filgueira L, Pietschmann 
P, Thomas R. Rheumatoid arthritis synovium contains plasmacytoid den-
dritic cells. Arthritis Res Ther 2005; 7: R230-40.
17. Kinne RW, Bräuer R, Stuhlmüller B, Palombo-Kinne E, Burmester GR. 
Macrophages in rheumatoid arthritis. Arthritis Res 2000; 2: 189-202.
18. Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG. Elevated serum interleukin 
33 is associated with autoantibody production in patients with rheuma-
toid arthritis. J Rheumatol 2010; 37: 2006-13.
19. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role 
of proinflammatory cytokines in the pathophysiology of osteoarthritis. 
Nat Rev Rheumatol 2011; 7: 33-42.
20. Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani 
K, Nagashima T, Hayakawa M, Iwamoto M, Yoshio T, Tominaga S, Mino-
ta S. Increased levels of interleukin 33 in sera and synovial fluid from pa-
tients with active rheumatoid arthritis. J Rheumatol 2010; 37: 18-25.
21. Smithgall MD, Comeau MR, Yoon BP, Kaufman D, Armitage R, Smith 
DE. IL-33 amplifies both Th1- and Th2-type responses through its activi-
ty on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. 
Int Immunol 2008; 20: 1019-30.
22. Carter RW, Sweet MJ, Xu D, Klemenz R, Liew FY, Chan WL. Regulation 
of ST2L expression on T helper (Th) type 2 cells. Eur J Immunol 2001; 31: 
2979-85.
23. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gor-
don C, Buckley CD, Salmon M. Early rheumatoid arthritis is character-
ized by a distinct and transient synovial fluid cytokine profile of T cell and 
stromal cell origin. Arthritis Res Ther 2005; 7: R784-95.
24. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: 
the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-10.
25. Verri WA Jr, Souto FO, Vieira SM, Almeida SC, Fukada SY, Xu D, Alves-
Filho JC, Cunha TM, Guerrero AT, Mattos-Guimaraes RB, Oliveira FR, 
Teixeira MM, Silva JS, McInnes IB, Ferreira SH, Louzada-Junior P, Liew 
FY, Cunha FQ. IL-33 induces neutrophil migration in rheumatoid arthri-
tis and is a target of anti-TNF therapy. Ann Rheum Dis 2010; 69: 1697-703.
26. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O’Neill LA, Liew FY. ST2 
is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling Hong Y-S, et al.  •  IL-33 and IL-33 Receptor in RA
http://jkms.org   1139 http://dx.doi.org/10.3346/jkms.2011.26.9.1132
and maintains endotoxin tolerance. Nat Immunol 2004; 5: 373-9.
27. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, 
Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, 
is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S 
A 2007; 104: 282-7.
28. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, Okumura K, 
Saito H, Nakae S. Caspase-1, caspase-8, and calpain are dispensable for 
IL-33 release by macrophages. J Immunol 2009; 183: 7890-7.
29. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after mat-
uration by caspase-1. Proc Natl Acad Sci U S A 2009; 106: 9021-6.
AUTHOR SUMMARY
Measurement of Interleukin-33 (IL-33) and IL-33 Receptors (sST2 and ST2L)  
in Patients with Rheumatoid Arthritis
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Ho-Youn Kim and Jun-Ki Min
This study was conducted to determine the levels of IL-33 and sST2 in sera and synovial fluids from patients with rheumatoid 
arthritis (RA), osteoarthritis (OA), and healthy controls (HC). Mean levels of IL-33 and sST2 were higher in sera of RA patients than 
HC. And IL-33 concentration of synovial fluid was higher in RA than OA. On the other hand, synovial fluid level of sST2 did not 
differ between RA and OA. The serum levels of IL-33 and sST2 decreased together with C-reactive protein, after treatment with 
disease-modifying antirheumatic drugs in treatment-naive RA patients. Our results suggests that IL-33 is involved in the 
pathogenesis of RA and may reflect the degree of inflammatory condition in RA. 